Clinical characteristics and possible drug targets in autosomal dominant spinocerebellar ataxias

Laszlo Szpisjak, Denes Zadori, P. Klivényi, L. Vécsei

Research output: Contribution to journalReview article

Abstract

Background & Objective: The autosomal dominant spinocerebellar ataxias (SCAs) belong to a large and expanding group of neurodegenerative disorders. SCAs comprise more than 40 subtypes characterized by progressive ataxia as a common feature. The most prevalent diseases among SCAs are caused by CAG repeat expansions in the coding-region of the causative gene resulting in polyglutamine (polyQ) tract formation in the encoded protein. Unfortunately, there is no approved therapy to treat cerebellar motor dysfunction in SCA patients. In recent years, several studies have been conducted to recognize the clinical and pathophysiological aspects of the polyQ SCAs more accurately. This scientific progress has provided new opportunities to develop promising gene therapies, including RNA interference and antisense oligonucleotides. Conclusion: The aim of the current work is to give a brief summary of the clinical features of SCAs and to review the cardinal points of pathomechanisms of the most common polyQ SCAs. In addition, we review the last few year’s promising gene suppression therapies of the most frequent polyQ SCAs in animal models, on the basis of which human trials may be initiated in the near future.

Original languageEnglish
Pages (from-to)279-293
Number of pages15
JournalCNS and Neurological Disorders - Drug Targets
Volume18
Issue number4
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Spinocerebellar Ataxias
Pharmaceutical Preparations
Genetic Therapy
Cerebellar Diseases
Antisense Oligonucleotides
Ataxia
RNA Interference
Neurodegenerative Diseases
Animal Models
polyglutamine

Keywords

  • Antisense oligonucleotides
  • Ataxia
  • Dominant ataxia
  • Hereditary ataxia
  • Neurodegenerative diseases
  • RNA therapeutics
  • Spinocerebellar ataxia

ASJC Scopus subject areas

  • Neuroscience(all)
  • Pharmacology

Cite this

Clinical characteristics and possible drug targets in autosomal dominant spinocerebellar ataxias. / Szpisjak, Laszlo; Zadori, Denes; Klivényi, P.; Vécsei, L.

In: CNS and Neurological Disorders - Drug Targets, Vol. 18, No. 4, 01.01.2019, p. 279-293.

Research output: Contribution to journalReview article

@article{48bf50f506af414eba955b98f09e6615,
title = "Clinical characteristics and possible drug targets in autosomal dominant spinocerebellar ataxias",
abstract = "Background & Objective: The autosomal dominant spinocerebellar ataxias (SCAs) belong to a large and expanding group of neurodegenerative disorders. SCAs comprise more than 40 subtypes characterized by progressive ataxia as a common feature. The most prevalent diseases among SCAs are caused by CAG repeat expansions in the coding-region of the causative gene resulting in polyglutamine (polyQ) tract formation in the encoded protein. Unfortunately, there is no approved therapy to treat cerebellar motor dysfunction in SCA patients. In recent years, several studies have been conducted to recognize the clinical and pathophysiological aspects of the polyQ SCAs more accurately. This scientific progress has provided new opportunities to develop promising gene therapies, including RNA interference and antisense oligonucleotides. Conclusion: The aim of the current work is to give a brief summary of the clinical features of SCAs and to review the cardinal points of pathomechanisms of the most common polyQ SCAs. In addition, we review the last few year’s promising gene suppression therapies of the most frequent polyQ SCAs in animal models, on the basis of which human trials may be initiated in the near future.",
keywords = "Antisense oligonucleotides, Ataxia, Dominant ataxia, Hereditary ataxia, Neurodegenerative diseases, RNA therapeutics, Spinocerebellar ataxia",
author = "Laszlo Szpisjak and Denes Zadori and P. Kliv{\'e}nyi and L. V{\'e}csei",
year = "2019",
month = "1",
day = "1",
doi = "10.2174/1871527318666190311155846",
language = "English",
volume = "18",
pages = "279--293",
journal = "CNS and Neurological Disorders - Drug Targets",
issn = "1871-5273",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Clinical characteristics and possible drug targets in autosomal dominant spinocerebellar ataxias

AU - Szpisjak, Laszlo

AU - Zadori, Denes

AU - Klivényi, P.

AU - Vécsei, L.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background & Objective: The autosomal dominant spinocerebellar ataxias (SCAs) belong to a large and expanding group of neurodegenerative disorders. SCAs comprise more than 40 subtypes characterized by progressive ataxia as a common feature. The most prevalent diseases among SCAs are caused by CAG repeat expansions in the coding-region of the causative gene resulting in polyglutamine (polyQ) tract formation in the encoded protein. Unfortunately, there is no approved therapy to treat cerebellar motor dysfunction in SCA patients. In recent years, several studies have been conducted to recognize the clinical and pathophysiological aspects of the polyQ SCAs more accurately. This scientific progress has provided new opportunities to develop promising gene therapies, including RNA interference and antisense oligonucleotides. Conclusion: The aim of the current work is to give a brief summary of the clinical features of SCAs and to review the cardinal points of pathomechanisms of the most common polyQ SCAs. In addition, we review the last few year’s promising gene suppression therapies of the most frequent polyQ SCAs in animal models, on the basis of which human trials may be initiated in the near future.

AB - Background & Objective: The autosomal dominant spinocerebellar ataxias (SCAs) belong to a large and expanding group of neurodegenerative disorders. SCAs comprise more than 40 subtypes characterized by progressive ataxia as a common feature. The most prevalent diseases among SCAs are caused by CAG repeat expansions in the coding-region of the causative gene resulting in polyglutamine (polyQ) tract formation in the encoded protein. Unfortunately, there is no approved therapy to treat cerebellar motor dysfunction in SCA patients. In recent years, several studies have been conducted to recognize the clinical and pathophysiological aspects of the polyQ SCAs more accurately. This scientific progress has provided new opportunities to develop promising gene therapies, including RNA interference and antisense oligonucleotides. Conclusion: The aim of the current work is to give a brief summary of the clinical features of SCAs and to review the cardinal points of pathomechanisms of the most common polyQ SCAs. In addition, we review the last few year’s promising gene suppression therapies of the most frequent polyQ SCAs in animal models, on the basis of which human trials may be initiated in the near future.

KW - Antisense oligonucleotides

KW - Ataxia

KW - Dominant ataxia

KW - Hereditary ataxia

KW - Neurodegenerative diseases

KW - RNA therapeutics

KW - Spinocerebellar ataxia

UR - http://www.scopus.com/inward/record.url?scp=85070771761&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070771761&partnerID=8YFLogxK

U2 - 10.2174/1871527318666190311155846

DO - 10.2174/1871527318666190311155846

M3 - Review article

C2 - 30864514

AN - SCOPUS:85070771761

VL - 18

SP - 279

EP - 293

JO - CNS and Neurological Disorders - Drug Targets

JF - CNS and Neurological Disorders - Drug Targets

SN - 1871-5273

IS - 4

ER -